DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• DENTSPLY SIRONA has a consensus analyst rating of "Hold" from 14 brokerage firms, with three sell ratings, eight hold ratings, and three buy ratings. The average 12-month price target among recently updated analysts is about $13.55.
• Several analysts recently adjusted their views: Zacks upgraded the stock to hold, Barrington raised its target to $17 with an outperform rating, and Bank of America upgraded it to buy while lifting its target to $17. UBS also kept a buy rating but trimmed its price target to $17.
• Insiders have been buying shares, including directors Brian P. McKeon and Michael J. Barber, who purchased stock in June. The company also reported mixed quarterly results, missing EPS estimates but beating revenue expectations, while shares recently traded near $10.33, close to their 1-year low of $9.40.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) have received an average recommendation of "Hold" from the fourteen research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $13.5455.

Several research firms have recently commented on XRAY. Zacks Research raised DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a research report on Monday, March 2nd. Barrington Research increased their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an "outperform" rating in a research report on Monday, March 2nd. UBS Group cut their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Bank of America upgraded DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and increased their price target for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. Finally, Wells Fargo & Company increased their price objective on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 27th.

Insider Activity

In other news, Director Brian P. Mckeon bought 10,000 shares of DENTSPLY SIRONA stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Barber purchased 15,175 shares of the business's stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $9.88 per share, with a total value of $149,929.00. Following the purchase, the director directly owned 55,943 shares in the company, valued at approximately $552,716.84. The trade was a 37.22% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 35,160 shares of company stock worth $351,179 in the last three months. Company insiders own 0.46% of the company's stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds and other institutional investors have recently bought and sold shares of XRAY. Vanguard Group Inc. grew its position in shares of DENTSPLY SIRONA by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier's stock valued at $279,263,000 after purchasing an additional 869,566 shares in the last quarter. First Eagle Investment Management LLC raised its stake in shares of DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier's stock valued at $167,342,000 after acquiring an additional 458,744 shares during the last quarter. AQR Capital Management LLC raised its stake in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock worth $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC grew its holdings in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier's stock worth $129,445,000 after purchasing an additional 92,868 shares during the period. Finally, Southpoint Capital Advisors LP purchased a new stake in DENTSPLY SIRONA in the first quarter worth about $116,000,000. Institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Stock Performance

XRAY stock opened at $10.33 on Friday. The business's 50-day moving average price is $10.87 and its two-hundred day moving average price is $11.69. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The firm has a market cap of $2.07 billion, a PE ratio of -3.28, a P/E/G ratio of 1.19 and a beta of 0.89. DENTSPLY SIRONA has a 1-year low of $9.40 and a 1-year high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. During the same quarter last year, the firm earned $0.43 earnings per share. The business's revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, research analysts forecast that DENTSPLY SIRONA will post 1.42 earnings per share for the current year.

About DENTSPLY SIRONA

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.